The progressive forms of multiple sclerosis – primary progressive MS (PPMS) and secondary progressive MS (SPMS) – have presented neurologists with particular challenges for decades. Unlike relapsing-remitting MS (RRMS), where inflammation control through disease-modifying therapies is now the clinical standard, therapeutic progress in the progressive spectrum remains fragmentary. In recent years, however, new approaches have emerged: from targeted immunomodulators, Bruton’s tyrosine kinase inhibitors and remyelination strategies to innovative cell and gene therapies.
Autoren
- Tanja Schliebe
Publikation
- InFo NEUROLOGIE & PSYCHIATRIE
Related Topics
You May Also Like
- Shared decision making
Participatory decision-making using the example of diets for type 1 diabetes
- Patient-centered rounds in medicine
Aligning care with the patient
- Migraine and vascular regulation
CGRP-targeted migraine therapies for vascular risk patients
- Pediatric multiple sclerosis
Early high efficacy as the key to improving prognosis
- Case report, molecular basis and therapeutic implications
HER2-positive colorectal carcinoma with invasive micropapillary component
- Wound Care
Chronically infected wound on the lower leg – a case report
- From symptom to diagnosis
Dyspnea – thoracic lymphoma
- Hemophilia A and B